HER2 Support Group Forums - View Single Post - HER2 and Immunotherapy Studies for reference

agness · 10-06-2015, 02:52 AM

Novel Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients
http://immuno-oncologynews.com/2014/...ncer-patients/

The GP2 vaccine was injected subcutaneously every month for the first six months, followed by four cycles of booster shots every six months thereafter, with a follow-up period of approximately three years...

Among all patients, the disease-free survival (DFS) rate was 88% among those who received the vaccine and 81% in the control group, translating in a 37% reduction in recurrence. However, if patients who did not complete the trial were excluded, the results proved higher, with a 94% DFS rate in patients receiving combination therapy versus 85% in controls, a 57% risk reduction.

According to the team, women with HER2 +3 who were administered trastuzumab (a monoclonal antibody targeting the HER2/neu receptor) before receiving the vaccine, did not experience cancer recurrence, leading researchers to hypothesize that trastuzumab may act as a primer for the vaccine, since it stimulates CD4 T cells to initiate a complex immune response.

10-06-2015, 02:52 AM	#1
agness Senior Member Join Date: Aug 2014 Location: Seattle, WA Posts: 285	HER2 and Immunotherapy Studies for reference Novel Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients http://immuno-oncologynews.com/2014/...ncer-patients/ The GP2 vaccine was injected subcutaneously every month for the first six months, followed by four cycles of booster shots every six months thereafter, with a follow-up period of approximately three years... Among all patients, the disease-free survival (DFS) rate was 88% among those who received the vaccine and 81% in the control group, translating in a 37% reduction in recurrence. However, if patients who did not complete the trial were excluded, the results proved higher, with a 94% DFS rate in patients receiving combination therapy versus 85% in controls, a 57% risk reduction. According to the team, women with HER2 +3 who were administered trastuzumab (a monoclonal antibody targeting the HER2/neu receptor) before receiving the vaccine, did not experience cancer recurrence, leading researchers to hypothesize that trastuzumab may act as a primer for the vaccine, since it stimulates CD4 T cells to initiate a complex immune response. __________________ Dx 2/14 3b HER2+/HR- left breast, left axilla, internal mammary node (behind breast bone). Neoadjuvant TCHP 3/14-7/2. PCR 8/14 LX and SND. 10/21-12/9 Proton therapy to chest wall. Dx 7/20/15 cerebellar met 3.5x5cm HER2+/HR-/GATA3+ 7/23/15 Craniotomy. 7/29/15 bone scan clear. 8/3/15 PET clean scan. LINAC SRS (5 fractions) Sept 2015. 9/17/15 CSF NED, 9/24/15 CSF NED, 11/2/15 CSF NED. 10/27/15 atypical uptake in right cerebellum - inflammation? 12/1/15 Leptomeningeal dx. Starting IT Herceptin. 1/16 - 16 fractions of tomotherapy to cerebellum, break of IT Herceptin during rads, resume at 100 mg weekly 3/2016 - stable scan 5/2016 stable scan 7/2016 pseudoprogression? 9/2016 more LM, start new chemo protocol and IV therapy treatment with HBOT 11/2016 Cyberknife to temporal lobe, HBOT just prior 12/2016 - lesions starting to show shrinkage 8/2017 - Stable since Dec 2016. Temporal lobe lesion gone. Using TCM, naturopathic oncology, physical therapy, chiro, massage, medical qigong, and energetic healing modalities in tandem. Stops at nothing. Mother of 2 boys - ages 7 and 10 (8/2017) and a lovely partner with lots to live for.